• Revenue unchanged at $0
• Loss after tax up 37% to $23.6 million
• Net tangible assets per share increased to 39.7 cents

Clarity Pharmaceuticals Ltd has released its Appendix 4D financial statements for the half-year ended 31 December 2024. The company reported revenue from ordinary activities of $0, unchanged from the previous corresponding period. Loss from ordinary activities after tax attributable to the owners of Clarity Pharmaceuticals Ltd was $23,582,000, up 37% compared to the prior half-year. The loss for the consolidated entity after providing for income tax amounted to $23,581,592. There were no dividends paid, recommended, or declared during the current financial period. Net tangible assets per ordinary security increased from 20.2 cents in the previous period to 39.7 cents. The financial statements have been reviewed by Grant Thornton, who have issued an unmodified opinion.